Resolving shortages of prescription drugs: the case for public-private collaboration

The recent IJHPR article by Schwartzberg and colleagues presents new data on the growing problem of prescription drug shortages. Resolving shortages typically involves many participants: government, industry, physicians and healthcare facilities. Israel has a strong record of informal collaboration...

Descripción completa

Detalles Bibliográficos
Autor principal: Katz, Eric Efraim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424491/
https://www.ncbi.nlm.nih.gov/pubmed/28496968
http://dx.doi.org/10.1186/s13584-017-0152-5
_version_ 1783235147959631872
author Katz, Eric Efraim
author_facet Katz, Eric Efraim
author_sort Katz, Eric Efraim
collection PubMed
description The recent IJHPR article by Schwartzberg and colleagues presents new data on the growing problem of prescription drug shortages. Resolving shortages typically involves many participants: government, industry, physicians and healthcare facilities. Israel has a strong record of informal collaboration that can fix drug shortages quickly. The success of Israel’s informal collaborations, as well as its formal partnerships, deserves broader recognition at home and more attention from the international community.
format Online
Article
Text
id pubmed-5424491
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54244912017-05-11 Resolving shortages of prescription drugs: the case for public-private collaboration Katz, Eric Efraim Isr J Health Policy Res Commentary The recent IJHPR article by Schwartzberg and colleagues presents new data on the growing problem of prescription drug shortages. Resolving shortages typically involves many participants: government, industry, physicians and healthcare facilities. Israel has a strong record of informal collaboration that can fix drug shortages quickly. The success of Israel’s informal collaborations, as well as its formal partnerships, deserves broader recognition at home and more attention from the international community. BioMed Central 2017-05-10 /pmc/articles/PMC5424491/ /pubmed/28496968 http://dx.doi.org/10.1186/s13584-017-0152-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Katz, Eric Efraim
Resolving shortages of prescription drugs: the case for public-private collaboration
title Resolving shortages of prescription drugs: the case for public-private collaboration
title_full Resolving shortages of prescription drugs: the case for public-private collaboration
title_fullStr Resolving shortages of prescription drugs: the case for public-private collaboration
title_full_unstemmed Resolving shortages of prescription drugs: the case for public-private collaboration
title_short Resolving shortages of prescription drugs: the case for public-private collaboration
title_sort resolving shortages of prescription drugs: the case for public-private collaboration
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424491/
https://www.ncbi.nlm.nih.gov/pubmed/28496968
http://dx.doi.org/10.1186/s13584-017-0152-5
work_keys_str_mv AT katzericefraim resolvingshortagesofprescriptiondrugsthecaseforpublicprivatecollaboration